PacBio Announces Fourth Quarter and Fiscal Year 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Pacific Bio (PACB) Misses Q4 EPS by 2c
February 15, 2022 4:14 PM ESTPacific Bio (NASDAQ: PACB) reported Q4 EPS of ($0.30), $0.02 worse than the analyst estimate of ($0.28). Revenue for the quarter came in at $36 million versus the consensus estimate of $36.12 million.
For earnings history and earnings-related data on Pacific Bio (PACB) click here.
... More